Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts
Open Access
- 26 March 2008
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 83 (8), 611-613
- https://doi.org/10.1002/ajh.21192
Abstract
In a retrospective study of 126 adult patients with French–American–British‐defined refractory anemia with ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive of survival outcome (P < 0.0001). In addition, red blood cell (RBC) transfusion requirement at diagnosis (P = 0.001), but not the number of RBC units transfused during the disease course (P = 0.17), was independently associated with inferior survival. There were no correlations between survival and serum ferritin level, measured either at diagnosis (median 567 ng/mL, range 16–3,475; P = 0.24) or during follow‐up (median 1,108 ng/mL; range 238–43,500; P = 0.72). Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥1,000 ng/mL at diagnosis or peak serum ferritin levels of 5,000 ng/mL during follow‐up. The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in “good risk” myelodysplastic syndrome. Am. J. Hematol., 2008.Keywords
This publication has 17 references indexed in Scilit:
- No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* techniqueAmerican Journal of Hematology, 2007
- Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long‐term blood transfusionsBritish Journal of Haematology, 2007
- Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemiaBlood, 2007
- Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicitiesExpert Opinion on Drug Safety, 2007
- Myelodysplastic syndromesCancer, 2007
- Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classificationLeukemia, 2007
- Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questionsBlood, 2006
- Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision MakingJournal of Clinical Oncology, 2005
- A Comparative Review of Classification Systems in Myelodysplastic Syndromes (MDS)Seminars in Oncology, 2005
- The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institutionBritish Journal of Haematology, 1995